Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Enzyme test could open door to new dementia therapy

NCT ID NCT05304195

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study measured the activity of an enzyme called glucocerebrosidase in 236 people with and without Lewy body dementia. The goal was to see if lower enzyme activity could help identify patients who might benefit from treatments already used for Gaucher disease. The study did not test any treatment, but its results could guide future therapeutic trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study shows that glucocerebrosidase activity is lower in people with Lewy body dementia, it could point toward using existing Gaucher disease treatments for this condition.
What could go wrong
This is an observational study that only measures enzyme activity—it does not test any treatment. The results may not lead to a therapy, and any future trials would still need to prove safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

236 people

The number who actually took part.

Started

Feb 2023

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

118 patients and 118 control subjects Patients and controls (often an accompanying person) will be selected during a routine visit for the patient's DLB

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for patients : * Male or female aged ≥ 50 years old * Presence of an accompanying person * Dementia with lewy bodies according to the revised criteria of Mc Keith 2017 Inclusion Criteria for controls: * Male or female aged ≥ 50 years old * Absence of cognitive impairment and clinical element for a neurodegenerative disease Exclusion Criteria for patients: * Other neurodegenerative disease * Gaucher disease Exclusion Criteria for controls: * Neurodegenerative disease * Cognitive impairment of all causes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dementia with lewy bodies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lewy body dementia Lewy Body Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dementia with lewy bodies

Contacts and locations

Locations

  • Centre de neurologie Cognitive

    Paris, France, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.